In the chemoimmunotherapy regimen group, the median age was 66 (range: 39–79) years, 22 patients (57.9%) were of male sex, five (13.2%) had ECOG PS 2/3, three (7.9%) had uncommon EGFR mutations, 19 (50.0%) had a history of smoking, and nine (23.7%) had a PD-L1 tumor proportion score greater than or equal to 50%. The gene discussed is EGFR; the disease is neoplasm.